In Amsterdam this week, Eli Lilly offered the world a glimpse of what may be medicine's first meaningful foothold against Alzheimer's disease — a drug that does not stop the forgetting, but slows it. Donanemab, tested in 1,700 patients over 18 months, bought some people four to seven additional months before decline deepened, a modest gift measured against an immodest disease. Yet the drug carries within it the shadow of its own promise: brain swelling, bleeding, and at least three deaths in trials remind us that the border between intervention and harm is rarely clean. As the FDA weighs appro
Eli Lilly's Alzheimer's drug shows modest promise, but risks remain
At least three deaths linked to the drug's adverse brain effects during clinical trials.
Four to seven months of slowed decline, but the cost is brain swelling or bleeding.
Mark
So the drug works—it slows decline by four to seven months. Why does that feel like both a victory and a problem?
Mimi
Because four to seven months is real time for someone living with Alzheimer's, but it's also not a cure, and the way you get those months matters. You're getting monthly infusions that can cause your brain to swell or bleed.
Mark
And people died in the trial?
Mimi
At least three deaths were linked to those adverse effects. That's not a huge number in a 1,700-person trial, but it's not nothing either. It's the thing that makes a doctor pause.
Mark
The company says it's like diabetes treatment—you manage it, you don't cure it. Is that fair?
Mimi
It's fair as far as it goes. But diabetes medication doesn't typically cause your brain to swell. The comparison breaks down when you're talking about risk-benefit in a disease where people are already losing themselves.
Mark
Who decides if this is worth it?
Mimi
That's the real question. The patient has to decide, their doctor has to decide, and then the insurance company has to decide if they'll pay for it. Right now, we don't even know which patients benefit most—just that earlier treatment works better.
Mark
So it's not ready yet.
Mimi
It's ready as a tool. Whether it's ready as a treatment for most people—that's still being written.
The Pulse
- For the first time, a drug targeting amyloid protein buildup has shown measurable — if modest — results in slowing Alzheimer's progression, energizing a field long starved of genuine breakthroughs.
- The trial's shadow is real: brain swelling and bleeding affected participants, and at least three deaths were linked to the drug's adverse effects, forcing an uncomfortable reckoning alongside the cautious optimism.
- Independent researchers are pushing back, arguing that a drug this risky, expensive, and difficult to administer demands far more dramatic benefits to justify widespread use.
- Eli Lilly is now seeking FDA approval, while the Alzheimer's Association calls the evidence convincing — setting up a collision between scientific enthusiasm and the harder math of patient safety and access.
- The drug's benefits appear most pronounced in the earliest stages of disease, meaning the entire enterprise hinges on early diagnosis — a capability the healthcare system is not yet reliably equipped to deliver at scale.
In Amsterdam this week, Eli Lilly offered the world a glimpse of what may be medicine's first meaningful foothold against Alzheimer's disease — a drug that does not stop the forgetting, but slows it. Donanemab, tested in 1,700 patients over 18 months, bought some people four to seven additional months before decline deepened, a modest gift measured against an immodest disease. Yet the drug carries within it the shadow of its own promise: brain swelling, bleeding, and at least three deaths in trials remind us that the border between intervention and harm is rarely clean. As the FDA weighs approval, humanity finds itself once again at the familiar threshold — hope tempered by cost, urgency tempered by risk.
Eli Lilly this week unveiled results for donanemab, an experimental Alzheimer's drug, at the Alzheimer's Association International Conference in Amsterdam, publishing simultaneously in the Journal of the American Medical Association. The trial — 1,700 patients aged 60 to 85, followed for 18 months — found that those receiving monthly infusions of the drug declined more slowly than those on placebo. At the earliest stage of disease, 47 percent of donanemab recipients showed no progression over a full year. Lilly and the Alzheimer's Association framed this as meaningful: a chance for patients to hold onto independence a little longer, perhaps four to seven months beyond what the disease would otherwise allow.
But the drug's promise arrives wrapped in serious risk. Donanemab can cause the brain to swell or bleed, and at least three deaths during the trial were linked to these complications. The drug works by the same mechanism as Leqembi, a recently FDA-approved therapy — synthetic antibodies that clear amyloid plaques from the brain — and shares the same potential for harm.
Skepticism has followed the headlines. Dr. Eric Widera of UC San Francisco noted in an editorial that the benefits would be far more persuasive if the drug were safe, cheap, and simple to administer. It is none of those things. Which patients should receive it, and whether the benefit would feel meaningful in their daily lives, remains an open question.
Lilly's Dr. John Sims compared donanemab to diabetes treatment — not a cure, but a real intervention. The company is now seeking FDA approval. The Alzheimer's Association's Maria Carrillo called the evidence thoroughly convincing. Yet the true reckoning lies ahead: whether a few additional months of clearer thinking are worth the risk of brain bleeding, swelling, or death — and who gets to make that call.
Eli Lilly presented findings this week on donanemab, an experimental drug that appears to slow the cognitive decline of early-stage Alzheimer's patients by somewhere between four and seven months. The company unveiled the results at the Alzheimer's Association International Conference in Amsterdam on Monday, simultaneously publishing the data in the Journal of the American Medical Association. It's a moment the field has been waiting for—the first real sign that targeting the buildup of amyloid proteins in the brain might actually matter for how people experience the disease.
The trial enrolled 1,700 patients between 60 and 85 years old, all in the disease's early stages, and ran for 18 months. Participants received monthly infusions of either donanemab or a placebo. The results were measurable but not dramatic: those who got the drug declined more slowly than those who got dummy infusions. At the earliest stage of disease, 47 percent of donanemab recipients showed no progression over the course of a year—a finding that Lilly and the Alzheimer's Association framed as meaningful, a chance for people to hold onto independence and autonomy a little longer.
But the drug comes with a serious catch. It can cause the brain to swell or bleed, adverse effects that the company disclosed in its presentation. The trial linked these complications to at least three deaths. Both donanemab and Leqembi, another amyloid-targeting drug recently approved by the FDA, carry this same risk. They work by the same mechanism—synthetic antibodies that strip away the protein plaques thought to drive Alzheimer's damage—and they carry the same potential for harm.
The modest gains have prompted skepticism among independent researchers. Dr. Eric Widera of the University of California, San Francisco, writing in an editorial alongside Lilly's published data, noted that the benefits would be far more compelling if the drug were low-risk, inexpensive, and easy to administer. It is none of those things. The question of which patients should receive the drug, and how noticeable the benefit would actually be in their daily lives, remains unanswered by the research.
Lilly's Dr. John Sims framed the findings as a step forward, comparing the drug to diabetes treatment—not a cure, but a meaningful intervention. The company is now seeking FDA approval. The Alzheimer's Association's chief science officer, Maria Carrillo, called the evidence "thoroughly convincing," arguing that removing amyloid from the brain is associated with significant slowing of disease progression. Yet the calculus for patients, doctors, and insurance companies will hinge on whether those extra months of cognitive function are worth the risk of brain swelling, bleeding, or death. That conversation is just beginning.
Notable Quotes
We don't cure the disease. Diabetes doesn't have a cure either—it doesn't mean you can't have very meaningful treatments for patients.— Dr. John Sims, Eli Lilly
The modest benefits would likely not be questioned if amyloid antibodies were low risk, inexpensive and simple to administer. However, they are none of these.— Dr. Eric Widera, University of California, San Francisco
Want the full story?
Read the original at New York Daily News ↗
Health & Medicine